Top

Published in:

Open Access 01-04-2018 | Preclinical study

Functional transcriptomic annotation and protein–protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer

Authors: Miriam Nuncia-Cantarero, Sandra Martinez-Canales, Fernando Andrés-Pretel, Gabriel Santpere, Alberto Ocaña, Eva Maria Galan-Moya

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Abstract

Purpose

Although obesity is a risk factor for breast cancer, little effort has been made in the identification of druggable molecular alterations in obese–breast cancer patients. Tumors are controlled by their surrounding microenvironment, in which the adipose tissue is a main component. In this work, we intended to describe molecular alterations at a transcriptomic and protein–protein interaction (PPI) level between obese and non-obese patients.

Methods and results

Gene expression data of 269 primary breast tumors were compared between normal-weight (BMI < 25, n = 130) and obese (IMC > 30, n = 139) patients. No significant differences were found for the global breast cancer population. However, within the luminal A subtype, upregulation of 81 genes was observed in the obese group (FC ≥ 1.4). Next, we explored the association of these genes with patient outcome, observing that 39 were linked with detrimental outcome. Their PPI map formed highly compact cluster and functional annotation analyses showed that cell cycle, cell proliferation, cell differentiation, and cellular response to extracellular stimuli were the more altered functions. Combined analyses of genes within the described functions are correlated with poor outcome. PPI network analyses for each function were to search for druggable opportunities. We identified 16 potentially druggable candidates. Among them, NEK2, BIRC5, and TOP2A were also found to be amplified in breast cancer, suggesting that they could act as strategic players in the obese-deregulated transcriptome.

Conclusion

In summary, our in silico analysis describes molecular alterations of luminal A tumors and proposes a druggable PPI network in obese patients with potential for translation to the clinical practice.

Available only for authorised users

Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Prev Biomark 25:16–27. https://doi.org/10.1158/1055-9965.EPI-15-0578 CrossRef

Beroukhim R, Mermel CH, Porter D et al (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463:899–905. https://doi.org/10.1038/nature08822 CrossRefPubMedPubMedCentral

Howell A, Anderson AS, Clarke RB et al (2014) Risk determination and prevention of breast cancer. Breast Cancer Res BCR 16:446. https://doi.org/10.1186/s13058-014-0446-2 CrossRefPubMed

van Gemert WA, Lanting CI, Goldbohm RA et al (2015) The proportion of postmenopausal breast cancer cases in the Netherlands attributable to lifestyle-related risk factors. Breast Cancer Res Treat 152:155–162. https://doi.org/10.1007/s10549-015-3447-7 CrossRefPubMedPubMedCentral

Crujeiras AB, Cabia B, Carreira MC et al (2016) Secreted factors derived from obese visceral adipose tissue regulate the expression of breast malignant transformation genes. Int J Obes 2005 40:514–523. https://doi.org/10.1038/ijo.2015.208

Bussard KM, Mutkus L, Stumpf K et al (2016) Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res BCR 18:84. https://doi.org/10.1186/s13058-016-0740-2 CrossRefPubMed

Cirri P, Chiarugi P (2012) Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev 31:195–208. https://doi.org/10.1007/s10555-011-9340-x CrossRefPubMed

Mao Y, Keller ET, Garfield DH et al (2013) Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 32:303–315. https://doi.org/10.1007/s10555-012-9415-3 CrossRefPubMedPubMedCentral

Denduluri SK, Idowu O, Wang Z et al (2015) Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2:13–25. https://doi.org/10.1016/j.gendis.2014.10.004 CrossRefPubMed

10.

Strong AL, Strong TA, Rhodes LV et al (2013) Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Res BCR 15:R102. https://doi.org/10.1186/bcr3569 CrossRefPubMed

11.

Turkoz FP, Solak M, Petekkaya I et al (2013) The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J BUON Off J Balk Union Oncol 18:335–341

12.

Booth A, Magnuson A, Fouts J, Foster M (2015) Adipose tissue, obesity and adipokines: role in cancer promotion. Horm Mol Biol Clin Investig 21:57–74. https://doi.org/10.1515/hmbci-2014-0037 PubMed

13.

Ciriello G, Gatza ML, Beck AH et al (2015) Comprehensive molecular portraits of invasive lobular breast cancer. Cell 163:506–519. https://doi.org/10.1016/j.cell.2015.09.033 CrossRefPubMedPubMedCentral

14.

Mihály Z, Kormos M, Lánczky A et al (2013) A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. Breast Cancer Res Treat 140:219–232. https://doi.org/10.1007/s10549-013-2622-y CrossRefPubMed

15.

Pavlopoulos GA, Secrier M, Moschopoulos CN et al (2011) Using graph theory to analyze biological networks. BioData Min 4:10. https://doi.org/10.1186/1756-0381-4-10 CrossRefPubMedPubMedCentral

16.

Athanasios A, Charalampos V, Vasileios T, Ashraf GM (2016) Recent updates on the application of protein-protein interaction network in drug discovery. Curr Drug Metab

17.

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095 CrossRefPubMed

18.

Toro AL, Costantino NS, Shriver CD et al (2016) Effect of obesity on molecular characteristics of invasive breast tumors: gene expression analysis in a large cohort of female patients. BMC Obes 3:22. https://doi.org/10.1186/s40608-016-0103-7 CrossRefPubMedPubMedCentral

19.

Pérez-Peña J, Serrano-Heras G, Montero JC et al (2016) In silico analysis guides selection of bet inhibitors for triple-negative breast cancer treatment. Mol Cancer Ther 15:1823–1833. https://doi.org/10.1158/1535-7163.MCT-16-0004 CrossRefPubMed

20.

Ocaña A, Pérez-Peña J, Alcaraz-Sanabria A et al (2016) In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases. Oncotarget 7:22865–22872. https://doi.org/10.18632/oncotarget.8118 PubMedPubMedCentral

21.

Appierto V, Tiberio P, Cavadini E et al (2009) Antimitotic effect of the retinoid 4-oxo-fenretinide through inhibition of tubulin polymerization: a novel mechanism of retinoid growth-inhibitory activity. Mol Cancer Ther 8:3360–3368. https://doi.org/10.1158/1535-7163.MCT-09-0798 CrossRefPubMed

22.

Sun X, Zhangyuan G, Shi L et al (2017) Prognostic and clinicopathological significance of cyclin B expression in patients with breast cancer: a meta-analysis. Medicine (Baltimore) 96:e6860. https://doi.org/10.1097/MD.0000000000006860 CrossRef

23.

Rinaldetti S, Wirtz RM, Worst TS et al (2017) FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget. https://doi.org/10.18632/oncotarget.17394 PubMedPubMedCentral

24.

Masuda H, Zhang D, Bartholomeusz C et al (2012) Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 136:331–345. https://doi.org/10.1007/s10549-012-2289-9 CrossRefPubMed

25.

Xiao Q, Chen Z, Jin X et al (2017) The many postures of noncanonical Wnt signaling in development and diseases. Biomed Pharmacother Biomed Pharmacother 93:359–369. https://doi.org/10.1016/j.biopha.2017.06.061 CrossRefPubMed

26.

Fuster JJ, Zuriaga MA, Ngo DT-M et al (2015) Noncanonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. Diabetes 64:1235–1248. https://doi.org/10.2337/db14-1164 CrossRefPubMed

27.

Gauger KJ, Bassa LM, Henchey EM et al (2014) The effects of diet induced obesity on breast cancer associated pathways in mice deficient in SFRP1. Mol Cancer 13:117. https://doi.org/10.1186/1476-4598-13-117 CrossRefPubMedPubMedCentral

28.

Ramakrishnan A-B, Cadigan KM (2017) Wnt target genes and where to find them. F1000Research 6:746. https://doi.org/10.12688/f1000research.11034.1 CrossRefPubMedPubMedCentral

29.

Safari-Alighiarloo N, Taghizadeh M, Rezaei-Tavirani M et al (2014) Protein–protein interaction networks (PPI) and complex diseases. Gastroenterol Hepatol Bed Bench 7:17–31PubMedPubMedCentral

30.

Wagner AH, Coffman AC, Ainscough BJ et al (2016) DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucl Acids Res 44:D1036–1044. https://doi.org/10.1093/nar/gkv1165 CrossRefPubMed

31.

Dominguez-Brauer C, Thu KL, Mason JM et al (2015) Targeting mitosis in cancer: emerging strategies. Mol Cell 60:524–536. https://doi.org/10.1016/j.molcel.2015.11.006 CrossRefPubMed

32.

Tubbs R, Barlow WE, Budd GT et al (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol Off J Am Soc Clin Oncol 27:3881–3886. https://doi.org/10.1200/JCO.2008.20.1566 CrossRef

33.

Bourdakou MM, Athanasiadis EI, Spyrou GM (2016) Discovering gene re-ranking efficiency and conserved gene-gene relationships derived from gene co-expression network analysis on breast cancer data. Sci Rep 6:20518. https://doi.org/10.1038/srep20518 CrossRefPubMedPubMedCentral

34.

Ocaña A, Pérez-Peña J, Díez-González L et al (2016) Transcriptomic analyses identify association between mitotic kinases, PDZ-binding kinase and BUB1, and clinical outcome in breast cancer. Breast Cancer Res Treat 156:1–8. https://doi.org/10.1007/s10549-016-3720-4 CrossRefPubMed

35.

Cross RA, McAinsh A (2014) Prime movers: the mechanochemistry of mitotic kinesins. Nat Rev Mol Cell Biol 15:257–271. https://doi.org/10.1038/nrm3768 CrossRefPubMed

36.

Rath O, Kozielski F (2012) Kinesins and cancer. Nat Rev Cancer 12:527–539. https://doi.org/10.1038/nrc3310 CrossRefPubMed

37.

Groner B, Weiss A (2014) Targeting survivin in cancer: novel drug development approaches. BioDrugs Clin Immunother Biopharm Gene Ther 28:27–39. https://doi.org/10.1007/s40259-013-0058-x

38.

Hamy AS, Bieche I, Lehmann-Che J et al (2016) BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. Breast Cancer Res Treat 159:499–511. https://doi.org/10.1007/s10549-016-3961-2 CrossRefPubMed

39.

Hayward DG, Clarke RB, Faragher AJ et al (2004) The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res 64:7370–7376. https://doi.org/10.1158/0008-5472.CAN-04-0960 CrossRefPubMed

40.

Tsunoda N, Kokuryo T, Oda K et al (2009) Nek2 as a novel molecular target for the treatment of breast carcinoma. Cancer Sci 100:111–116. https://doi.org/10.1111/j.1349-7006.2008.01007.x CrossRefPubMed

41.

Zhou W, Yang Y, Xia J et al (2013) NEK2 induces drug Resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers. Cancer Cell 23:48–62. https://doi.org/10.1016/j.ccr.2012.12.001 CrossRefPubMedPubMedCentral

42.

Cappello P, Blaser H, Gorrini C et al (2014) Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene 33:2375–2384. https://doi.org/10.1038/onc.2013.183 CrossRefPubMed

43.

Fang Y, Zhang X (2016) Targeting NEK2 as a promising therapeutic approach for cancer treatment. Cell Cycle 15:895–907. https://doi.org/10.1080/15384101.2016.1152430 CrossRefPubMedPubMedCentral

Title: Functional transcriptomic annotation and protein–protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer
Authors: Miriam Nuncia-Cantarero
Sandra Martinez-Canales
Fernando Andrés-Pretel
Gabriel Santpere
Alberto Ocaña
Eva Maria Galan-Moya
Publication date: 01-04-2018
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-017-4652-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods and results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2018

Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry

Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study

Consideration of population and cultural factors in American Indian/Alaskan Native (AIAN) research

Long-term use of basal insulin and the risk of breast cancer

High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients

How reliable are the available safety data on hormonal stimulation for fertility preservation in young women with newly diagnosed early breast cancer?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer